106 related articles for article (PubMed ID: 26543544)
1. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
Chen Y; Ning G; Wang C; Gong Y; Patel S; Zhang C; Izumoto T; Woerle HJ; Wang W
J Diabetes Investig; 2015 Nov; 6(6):692-8. PubMed ID: 26543544
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Davidson JA; Lajara R; Aguilar RB; Mattheus M; Woerle HJ; von Eynatten M
BMJ Open Diabetes Res Care; 2014; 2(1):e000020. PubMed ID: 25452864
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Zeng Z; Choi DS; Mohan V; Emser A; Siddiqui K; Gong Y; Patel S; Woerle HJ
Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
7. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
Del Prato S; Barnett AH; Huisman H; Neubacher D; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2011 Mar; 13(3):258-67. PubMed ID: 21205122
[TBL] [Abstract][Full Text] [Related]
8. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
Ning G; Bandgar T; Hehnke U; Lee J; Chan JCN
Adv Ther; 2017 Sep; 34(9):2150-2162. PubMed ID: 28819835
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.
Kanasaki K; Qu S; Yamamoto F; Schepers C; Sani Simões R; Yabe D; Ji L
Expert Opin Drug Saf; 2022 Mar; 21(3):425-434. PubMed ID: 34711126
[TBL] [Abstract][Full Text] [Related]
11. Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial.
Ma RC; Del Prato S; Gallwitz B; Shivane VK; Lewis-D'Agostino D; Bailes Z; Patel S; Lee J; von Eynatten M; Di Domenico M; Ross SA
J Diabetes Investig; 2017 Sep; 9(3):579-86. PubMed ID: 28921919
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study.
Deshmukh V; Sathyanarayana S; Menon S; Patil S; Jones R; Uppal S; Siddiqui K
Indian J Endocrinol Metab; 2015; 19(2):256-61. PubMed ID: 25729688
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Gomis R; Owens DR; Taskinen MR; Del Prato S; Patel S; Pivovarova A; Schlosser A; Woerle HJ
Int J Clin Pract; 2012 Aug; 66(8):731-740. PubMed ID: 22691164
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study.
Thrasher J; Daniels K; Patel S; Whetteckey J; Woerle HJ
Endocr Pract; 2014 May; 20(5):412-20. PubMed ID: 24326003
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials.
Inagaki N; Sheu WH; Owens DR; Crowe S; Bhandari A; Gong Y; Patel S
J Diabetes Complications; 2016; 30(8):1622-1630. PubMed ID: 27499458
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials.
Lehrke M; Leiter LA; Hehnke U; Thiemann S; Bhandari A; Meinicke T; Johansen OE
J Diabetes Complications; 2016; 30(7):1378-84. PubMed ID: 27396241
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial.
Mori K; Emoto M; Shoji T; Inaba M
BMJ Open Diabetes Res Care; 2016; 4(1):e000265. PubMed ID: 27547421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
